Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 12/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | CHRNA1 | P02708 | 4/20 | 0.42 |
| ▸ | CHRNG | P07510 | 4/20 | 0.42 |
| ▸ | CHRNB1 | P11230 | 4/20 | 0.42 |
| ▸ | CHRND | Q07001 | 4/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30971350 | 0.89 | FOLH1 (0.51) | FOLH1CTSBCTSSCTSK | |
| SCHEMBL29335966 | 0.89 | FOLH1 (0.51) | FOLH1CTSBCTSSCTSK | |
| SCHEMBL29678991 | 0.87 | FOLH1 (0.48) | FOLH1CTSBCTSSCTSK | |
| SCHEMBL26222813 | 0.87 | FOLH1 (0.48) | FOLH1CTSBCTSSCTSK | |
| SCHEMBL29678852 | 0.87 | FOLH1 (0.48) | FOLH1CTSBCTSSCTSK | |
| SCHEMBL29008427 | 0.87 | FOLH1 (0.48) | FOLH1CTSBCTSSCTSK | |
| SCHEMBL29678910 | 0.87 | FOLH1 (0.48) | FOLH1CTSBCTSSCTSK | |
| SCHEMBL29678941 | 0.87 | FOLH1 (0.53) | FOLH1CTSBCTSSCTSK | |
| SCHEMBL29335184 | 0.86 | CTSB (0.57) | FOLH1CTSBCTSSCTSK | |
| SCHEMBL29679033 | 0.86 | FOLH1 (0.59) | FOLH1CTSBCTSSCTSKCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230072421-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | BAYER AS (NO) | 2023-03-09 | — | — | US | disclosed |
| EP-4003959-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | Bayer AS (NO) | 2022-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230072421-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | KLK3, AR, SHBG | FOLH1 43/4885CTSB 1487/4885CTSS 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.